Application of tumor gene sequencing technology for clinical molecular diagnosis of non-small cell lung cancer
10.3760/cma.j.cn114452-20240705-00354
- VernacularTitle:肿瘤基因测序技术在非小细胞肺癌临床分子诊断中的应用
- Author:
Kunbo ZHU
1
;
Mengxin YUAN
;
Jingwei WANG
;
Jian GU
;
Qian WU
;
Wanzhou XU
;
Yongqing TONG
Author Information
1. 武汉大学人民医院检验医学中心，武汉 430060
- Keywords:
Neoplasms;
Sequence;
Carcinoma, non-small-cell lung;
Molecular targeted therapy
- From:
Chinese Journal of Laboratory Medicine
2024;47(11):1242-1247
- CountryChina
- Language:Chinese
-
Abstract:
Non-small cell lung cancer (NSCLC) ranks the first among malignant tumors in China and even in the whole world. In recent years, the developement of genetic testing technology, particularly tumor gene sequencing, has provided a solid basis for the clinical molecular diagnosis of NSCLC, which has greatly increased the chances of patients benefiting from targeted therapy or immunotherapy, and ultimately extending their survival. Standardizing the use of tumor gene sequencing is crucial for the precision medicine in NSCLC. This paper discusses the normalization of tumor gene sequencing technology in the clinical molecular diagnostic pathway of NSCLC, which may promote the standardized use of tumor gene sequencing technology in targeted therapy or immunotherapy drug selection, toxicity and side effect prediction, efficacy monitoring, recurrence and prognosis evaluation of NSCLC patients. This article discusses the standardization of the application of tumor gene sequencing technology in the clinical molecular diagnosis pathway of NSCLC. Additionally, it offers a foundation for the uniform use of tumor gene sequencing technology in other solid tumors.
